Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix, Harbor Diversified, Altimmune, and UnitedHealth and Encourages Investors to Contact the Firm
For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
- For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases. - The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
- On January 6, 2021, UnitedHealth announced an agreement to acquire Change Healthcare (“Change”) and integrate it into its Optum business.
- As a result of this disclosure, the price of UnitedHealth stock declined by $27 per share, erasing nearly $25 billion in shareholder value.